Discontinued — last reported Q2 '22
ResMed Stock Issuance Proceeds decreased by 74.9% to $7.43M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 17.7%, from $9.02M to $7.43M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows an upward trend with a 18.5% CAGR.
An increase suggests the company is raising capital through equity, while a decrease indicates a reduction in equity-based financing.
Represents the cash inflows received by the company from the issuance of new common equity shares to investors or employ...
Standard line item in the financing section of the cash flow statement for all public companies.
other_proceeds_from_issuance_of_common_stock| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.03M | $4.35M | $19.10M | $2.81M | $21.12M | $2.61M | $22.06M | $983.00K | $23.49M | $983.00K | $19.52M | $4.89M | $27.70M | $8.38M | $26.88M | $9.02M | $30.16M | $8.21M | $29.56M | $7.43M |
| QoQ Change | — | -77.1% | +338.7% | -85.3% | +650.4% | -87.6% | +745.1% | -95.5% | >999% | -95.8% | >999% | -74.9% | +466.1% | -69.7% | +220.6% | -66.4% | +234.2% | -72.8% | +260.2% | -74.9% |
| YoY Change | — | — | — | — | +11.0% | -40.1% | +15.5% | -65.1% | +11.3% | -62.3% | -11.5% | +397.7% | +17.9% | +752.8% | +37.7% | +84.4% | +8.9% | -2.1% | +10.0% | -17.7% |